Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

被引：818

作者：

Bargou, Ralf ^{[2
,3
]}

Leo, Eugen ^{[1
,4
]}

Zugmaier, Gerhard ^{[1
,4
]}

Klinger, Matthias ^{[1
,4
]}

Goebeler, Mariele ^{[2
,3
]}

Knop, Stefan ^{[3
]}

Noppeney, Richard ^{[5
]}

Viardot, Andreas ^{[6
]}

Hess, Georg ^{[7
]}

Schuler, Martin ^{[8
]}

Einsele, Hermann ^{[3
]}

Brandl, Christian ^{[1
,4
]}

Wolf, Andreas ^{[1
,4
]}

Kirchinger, Petra ^{[1
,4
]}

Klappers, Petra ^{[1
,4
]}

Schmidt, Margit ^{[1
,4
]}

Riethmueller, Gert ^{[9
]}

Reinhardt, Carsten ^{[1
,4
]}

Baeuerle, Patrick A. ^{[1
,4
]}

Kufer, Peter ^{[1
,4
]}

机构：

[1] Micromet AG, D-81477 Munich, Germany

[2] Univ Wurzburg, Interdisciplinary Phase 1 2 Unit, D-97070 Wurzburg, Germany

[3] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany

[4] Micromet Inc, Bethesda, MD 20817 USA

[5] Univ Klinikum Essen, Klin Hamatol, Med Klin & Poliklin, D-45147 Essen, Germany

[6] Univ Ulm Klinikum, D-89081 Ulm, Germany

[7] Univ Mainz Klinikum, Med Klin & Poliklin 3, D-55131 Mainz, Germany

[8] Univ Klinikum Essen, Innere Tumorforsch Klin, D-45122 Essen, Germany

[9] Univ Munich, Inst Immunol, D-81333 Munich, Germany

来源：

SCIENCE | 2008年 / 321卷 / 5891期

关键词：

D O I：

10.1126/science.1158545

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non- Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell- engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.

引用

页码：974 / 977

页数：4

共 28 条

[1] BiTE: a new class of antibodies that recruit T-cells
Baeuerle, P. A.
Reinhardt, C.
Kufer, P.
[J]. DRUGS OF THE FUTURE, 2008, 33 (02) : 137 - 147
[2] The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
Brandl, Christian
Haas, Cornelia
d'Argouges, Sandrine
Fisch, Tanja
Kufer, Peter
Brischwein, Klaus
Prang, Nadja
Bargou, Ralf
Suzich, JoAnn
Baeuerle, Patrick A.
Hofmeister, Robert
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) : 1551 - 1563
[3] MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
Brischwein, K
Schlereth, B
Guller, B
Steiger, C
Wolf, A
Lutterbuese, R
Offner, S
Locher, M
Urbig, T
Raum, T
Kleindienst, P
Wimberger, P
Kimmig, R
Fichtner, I
Kufer, P
Hofmeister, R
da Silva, AJ
Baeuerle, PA
[J]. MOLECULAR IMMUNOLOGY, 2006, 43 (08) : 1129 - 1143
[4] Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Brischwein, Klaus
Parr, Larissa
Pflanz, Stefan
Volkland, Jorg
Lumsden, John
Klinger, Matthias
Locher, Mathias
Hammond, Scott A.
Kiener, Peter
Kufer, Peter
Schlereth, Bernd
Baeuerle, Patrick A.
[J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 798 - 807
[5] The international harmonization project for response criteria in lymphoma clinical trials
Cheson, Bruce D.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (05) : 841 - +
[6] Phenotypic characterization of human colorectal cancer stem cells
Dalerba, Piero
Dylla, Scott J.
Park, In-Kyung
Liu, Rui
Wang, Xinhao
Cho, Robert W.
Hoey, Timothy
Gurney, Austin
Huang, Emina H.
Simeone, Diane M.
Shelton, Andrew A.
Parmiani, Giorgio
Castelli, Chiara
Clarke, Michael F.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (24) : 10158 - 10163
[7] T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
Dreier, T
Baeuerle, PA
Fichtner, I
Grün, M
Schlereth, B
Lorenczewski, G
Kufer, P
Lutterbüse, R
Riethmüller, G
Gjorstrup, P
Bargou, RC
[J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (08) : 4397 - 4402
[8] Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
Dreier, T
Lorenczewski, G
Brandl, C
Hoffmann, P
Syring, U
Hanakam, F
Kufer, P
Riethmuller, G
Bargou, R
Baeuerle, PA
[J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (06) : 690 - 697
[9] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
Dudley, ME
Wunderlich, JR
Yang, JC
Sherry, RM
Topalian, SL
Restifo, NP
Royal, RE
Kammula, U
White, DE
Mavroukakis, SA
Rogers, LJ
Gracia, GJ
Jones, SA
Mangiameli, DP
Pelletier, MM
Gea-Banacloche, J
Robinson, MR
Berman, DM
Filie, AC
Abati, A
Rosenberg, SA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2346 - 2357
[10] Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Galon, Jerom
Costes, Anne
Sanchez-Cabo, Fatima
Kirilovsky, Amos
Mlecnik, Bernhard
Lagorce-Pages, Christine
Tosolini, Marie
Camus, Matthieu
Berger, Anne
Wind, Philippe
Zinzindohoue, Franck
Bruneval, Patrick
Cugnenc, Paul-Henri
Trajanoski, Zlatko
Fridman, Wolf-Herman
Pages, Franck
[J]. SCIENCE, 2006, 313 (5795) : 1960 - 1964

← 1 2 3 →